Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury...

NASDAQ Global Select Market in the US. Genmab's technology is licensed from Medarex to create fully human high affinity antibodies using transgenic mice. These...

entered in 2005 between Ono and Medarex.[citation needed] Through the research collaboration with Ono, it was invented at Medarex using its transgenic mice...

California, Berkeley. Clinical development of anti-CTLA4 was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. For his work in developing...

(1985–2011) Massone (company) (????- ) Mayne (2005–2007) Maxygen (1997–2013) Medarex (1987–2009) Meda (1995–2016) MedImmune (1988–2019) Medivation (2004–2016)...

during a major restructuring activity, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships...

monoclonal antibody for treatment for arthritis, which was co-developed with Medarex, Inc. In 2004, the United States Department of Justice began investigating...

was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School...

transformation of BMY, particularly following the acquisition by Levin of Medarex Inc. in July 2009, which positioned BMY as a leader in immunooncology....

the original on 6 April 2020. Retrieved 6 April 2020 – via Drugs.com. "Medarex to Receive Milestone Payment for Approval of Stelara (Ustekinumab) for...